secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001493152-24-001074
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal reports favorable preliminary safety for CDI-988 (Phase 1) and CC-42344 (Phase 2a) antivirals
--------------------------------------------------------------------------------

- CDI-988 (pan-norovirus/coronavirus 3CL protease inhibitor) Phase 1 in Australia shows favorable safety in single-ascending dose cohorts.
- CC-42344 (influenza A PB2 inhibitor) Phase 2a in UK shows favorable tolerability in first cohort of challenge study.
- Cocrystal expects to report topline results for both Phase 1 and Phase 2a studies in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224001074/0001493152-24-001074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224001074/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-001074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer